Press release
NUTEX HEALTH ANNOUNCES PRELIMINARY 2023 HEADLINE FINANCIALS AND PROVIDES UPDATE ON THE TIMING OF ITS 10-K FILING
HOUSTON, March 15, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated
About this update from Nutex Health Inc.
[{"type":"text","content":"HOUSTON, March 15, 2024 /PRNewswire/ -- Nutex Health Inc. (\"Nutex Health\" or the \"Company\") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 20 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced preliminary FY 2023 headline financials and provides an update on the anticipated timing for the filing of its 10-K for the year ended December 31, 2023.\n\nThe Company is finalizing its FY 2023 10-K and expects to file it with the SEC next week within the extension deadline allowed under the SEC rules.\nPreliminary financial information for FY 2023 is as follows:\nFinancial Highlights for the Year Ended December 31, 2023:\nTotal revenue of $247.6 million as compared to total revenue of $219.3 million for the year ended December 31, 2022.Net loss attributable to Nutex Health Inc. of $44.2 million (including a non-cash asset impairment charge of $29.1 million and a $1.1. million impairment charge for hospital closures) as compared to net loss attributable to Nutex Health of $424.8 for the year ended December 31, 2022.Adjusted EBITDA of $13.6 million as compared to Adjusted EBITDA of $12.6 million for the year ended December 31, 2022.Net cash from operating activities of $1.8 million.As of December 31, 2023, the Company had total assets of $398.5 million, including cash and cash equivalents of $22.3 million.Financial Highlights for the Three Months Ended December 31, 2023:\nTotal revenue of $69.7 million as compared to total revenue of $53.7 million for the three months ended December 31, 2022.Net loss attributable to Nutex Health of $30.0 million as compared to net loss attributable to Nutex Health of $14.8 million for the three months ended December 31, 2022.Adjusted EBITDA of $5.9 million as compared to Adjusted EBITDA of negative $5.9 million for the three months ended December 31, 2022.Note: These are preliminary financial results for fiscal year 2023 which may change when the Company's final FY 2023 financial information is filed on Form 10-K with the SEC. However, the Company's actual results are not expected to differ materially from those reflected in the preliminary results.\nNote: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in...